Alexander Renwick
Overview
Explore the profile of Alexander Renwick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
522
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Henke D, Renwick A, Zoeller J, Meena J, Neill N, Bowling E, et al.
NPJ Precis Oncol
. 2025 Feb;
9(1):39.
PMID: 39915634
Precision medicine relies on identifying reliable biomarkers for gene dependencies to tailor individualized therapeutic strategies. The advent of high-throughput technologies presents unprecedented opportunities to explore molecular disease mechanisms but also...
2.
Chiang I, Humphrey D, Mills R, Kaltzis P, Pachauri S, Graus M, et al.
EMBO Rep
. 2023 Aug;
24(10):e55043.
PMID: 37551717
The cardiac endothelium influences ventricular chamber development by coordinating trabeculation and compaction. However, the endothelial-specific molecular mechanisms mediating this coordination are not fully understood. Here, we identify the Sox7 transcription...
3.
Birly A, Renwick A, Patel P
Br J Hosp Med (Lond)
. 2022 Jun;
83(5):1-3.
PMID: 35653313
No abstract available.
4.
Nair A, Chung H, Sun T, Tyagi S, Dobrolecki L, Dominguez-Vidana R, et al.
Nat Med
. 2018 Mar;
24(4):505-511.
PMID: 29578538
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer diagnosed in more than 200,000 women each year and is recalcitrant to targeted therapies. Although TNBCs harbor multiple hyperactive...
5.
Xu X, De Angelis C, Burke K, Nardone A, Hu H, Qin L, et al.
Clin Cancer Res
. 2017 May;
23(17):5123-5134.
PMID: 28487443
Resistance to anti-HER2 therapies in HER2 breast cancer can occur through activation of alternative survival pathways or reactivation of the HER signaling network. Here we employed BT474 parental and treatment-resistant...
6.
Franco L, Bucasas K, Wells J, Nino D, Wang X, Zapata G, et al.
Elife
. 2016 Aug;
5.
PMID: 27576045
No abstract available.
7.
Mahamdallie S, Hanks S, Karlin K, Zachariou A, Perdeaux E, Ruark E, et al.
Nat Genet
. 2016 Mar;
48(4):473.
PMID: 27023775
No abstract available.
8.
Mahamdallie S, Hanks S, Karlin K, Zachariou A, Perdeaux E, Ruark E, et al.
Nat Genet
. 2015 Nov;
47(12):1471-4.
PMID: 26551668
Wilms tumor is the most common childhood renal cancer. To identify mutations that predispose to Wilms tumor, we are conducting exome sequencing studies. Here we describe 11 different inactivating mutations...
9.
Hsu T, Simon L, Neill N, Marcotte R, Sayad A, Bland C, et al.
Nature
. 2015 Sep;
525(7569):384-8.
PMID: 26331541
MYC (also known as c-MYC) overexpression or hyperactivation is one of the most common drivers of human cancer. Despite intensive study, the MYC oncogene remains recalcitrant to therapeutic inhibition. MYC...
10.
Karlin K, Mondal G, Hartman J, Tyagi S, Kurley S, Bland C, et al.
Cell Rep
. 2014 Dec;
9(4):1318-32.
PMID: 25453754
Defining the molecular networks that drive breast cancer has led to therapeutic interventions and improved patient survival. However, the aggressive triple-negative breast cancer subtype (TNBC) remains recalcitrant to targeted therapies...